Jefferies Lowers PT On Metabolix To $13

July 28, 2011 6:47 AM | 8 seconds read |

Jefferies & Company has lowered the price target on Metabolix MBLX from $15 to $13 and maintains its Buy rating.

Posted In: Price Target Analyst Ratings Biotechnology Health Care Jefferies & Company

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.